In a study of 122 healthy volunteers (32 men, 90 women 38 + 12y), participants taking 250 mg of Biothera’s Wellmune WGP daily for 12 weeks reported a statistically significant 58% reduction in upper respiratory tract infection symptoms, compared with individuals taking a placebo.

Using a Profile of Mood States (POMS) psychological survey to assess changes in mental and physical energy levels and overall well-being, the study demonstrated statistically significant benefits for the Wellmune WGP group. These participants rated their overall well-being and vigor 9.5% and 11% higher, respectively, compared with the placebo group.

GLH Nutrition, which conducted the study on behalf of Biothera, is an independent research & development organization that evaluates ingredients for food, beverage and dietary supplements. For further information: www.wellmune.com